IDNA

iShares Genomics Immunology and Healthcare ETF

IDNA seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.


Global

EQUITY

Rules-Based

MANAGEMENT STYLE

140.3 M

ASSETS UNDER MGMT

47 bp

EXPENSES
Fund Basics
Fund sponsorBlackrock
CategoryGlobal
Asset classEquity
Websitelink...
Inception dateJun 11, 2019
Assets (mns)$140
Expense ratio47 bp
CurrencyUSD
Sector Breakdown
Fund Structure
RegulationOpen-Ended Fund
DistributionsAnnually
Taxation1099
Stock selectionMarket Value
WeightingMarket Value
Holdings TransparencyFull
Derivatives-basedNo
Options availableYes
Currency hedgedNo
Fund of fundsNo
Top 10 Holdings Complete list  + 
EXELIXIS INC 6.6 %
REVOLUTION MEDICINES, INC. 5.7 %
GILEAD SCIENCES INC 5.7 %
BEIGENE, LTD. 5.4 %
INCYTE CORP 5.0 %
BIONTECH SE SPONSORED ADR 4.7 %
SAREPTA THERAPEUTICS INC 4.3 %
ROCHE HOLDING LTD 4.3 %
TAKEDA PHARMACEUTICAL CO LTD 4.0 %
SANOFI-AVENTIS 4.0 %
Constituent Breakdown
Number of holdings49
Herfindahl-Hirschman Index 367
Wgt avg mkt cap (mns)$42,902
Large cap (>$10bn)57.7%
Mid cap ($2-10bn)21.8%
Small cap (<$2bn)20.5%
Developed mkts.93.8%
Emerging mkts.5.8%
Country Exposure
UNITED STATES 66.1 %
CHINA 5.4 %
SWITZERLAND 5.3 %
JAPAN 5.1 %
GERMANY 5.0 %
FRANCE 4.2 %
BRITAIN 3.2 %
DENMARK 3.1 %
CANADA 0.7 %
SOUTH KOREA 0.7 %
Historical Performance


Standardized Performance (as of 11/30/2024)
 YTD1 YR2 YR3 YR5 YR10 YRIncep.
Total Returns 8.5% 21.9% -5.3% -18.7% -2.4% -- -1.3%
Volatility 20.6% 23.2% 24.8% 30.0% 31.0% -- --
Market Correlations
versus...BetaR-squared
S&P 5001.1258%
MSCI EAFE1.0046%
MSCI Emg Mkts0.8130%
Liquidity Measures
Avg. volume (000)28
Turnover0.5%
Avg. Bid/Ask (% of price)0.21%
ADV of underlying (mns)$3,892
Technical Indicators
Recent close$24.61
30d moving avg.$24.38
Annualized volatility25.7%
Relative strength (RSI)48
Short interest (ETF)0.0%
Short interest (underlying)0.0%
Distributions
Assets Under Management (mns)

Money Flows (mns)

Short Interest (as % of shares outstanding)

Long Money Flows (mns)

Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial

Risk and Returns: IDNA vs. Comps (1 YR)

Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.

Content on this tab for Individual & Professional subscribers only. Start your FREE trial

Results & Estimates
  2019 2020 2021 2022 2023 2024E 2025E  
Sales per share -- -- -- -- -- -- --
  change (%) -- -- -- -- -- -- --
Earnings per share -- -- -- -- -- -- --
  change (%) -- -- -- -- -- -- --
Dividends per share -- -- -- -- -- -- --
  change (%) -- -- -- -- -- -- --
Book value per share -- -- -- -- -- -- --
  change (%) -- -- -- -- -- -- --
Return on Equity
Net Margins
EPS Revision Activity (6 mo. ago = 100%)
Compound Annual Growth Rates

Content on this tab for Individual & Professional subscribers only. Start your FREE trial

Valuation Metrics
  2023 2024E Fwd Est 2025E
Price-to-sales --x --x --x --x
Price-to-earnings --x --x --x --x
Price-to-cash flow --x --x --x --x
Price-to-growth --x --x --x --x
Price-to-book value --x --x --x --x
Yield --% --% --x --%
3.8 1,987.9 3.9 1.2% --
Based on closing prices from 12/2/2024
Historical Valuation Trends Sample data. Subscribe for access.

SHOWING:
Price-to-Earnings
IDNA



Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.

Some content on this tab for Individual & Professional subscribers only. Start your FREE trial

ETF Research Center Rating

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.

ALTAR Score™

IDNA

-4.1%

Cat. Avg

4.0%


ALTAR Score™ Calculation

Category Overview
There are 377 funds in the Global Equity category, with an average ALTAR Score™ of 4.0% and a standard deviation of 4.6%. IDNA's ALTAR Score™ is approximately 1.8 standard deviations below the category average. This places IDNA in the 4th percentile among funds in the category.
Sell Side Consensus Rating

Sell-side recommendations on the ETF's individual constituents

IDNA
Peer Average
SELL
U/W
HOLD
O/W
BUY
Factor Scorecard

SIZE
VALUE
YIELD
MOMENTUM
VOLATILITY
QUALITY
Expense Analysis

Peer Group Rules-Based
Global Equity ETFs
# of ETFs 191
Avg. Expense Ratio 55.4 bp
Std. Deviation 17.5 bp
IDNA (47 bp) Percentile rank 32
Peer Group Expense Ratio Distribution


Total Cost of Ownership (TCO) Comparison
Expense (bp)
(A)
Avg. Bid/Ask (bp)
(B)
TCO (bp)
(A)+(B)
IDNA 47.0 20.9 67.9
Peer Avg. 57.1 40.0 97.1
  For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .